| Literature DB >> 34016948 |
Sophie Pauligk1, Maria Seidel1, Sophia Fürtjes1, Joseph A King1, Daniel Geisler1, Inger Hellerhoff1,2, Veit Roessner2, Ulrike Schmidt3, Thomas Goschke4, Henrik Walter5, Alexander Strobel4, Stefan Ehrlich6,7.
Abstract
A growing body of evidence suggests that a high level of self-control may, despite its positive effects, influence cognitive processing in an unfavorable manner. However, the affective costs of self-control have only rarely been investigated. Anorexia nervosa (AN) is an eating disorder that is often characterized by excessive self-control. Here, we used fMRI to explore whether over-control in AN may have negative affective consequences. 36 predominantly adolescent female AN patients and 36 age-matched healthy controls (HC) viewed negative and neutral pictures during two separate fMRI sessions before and after 10 min of rest. We tested whether abnormally elevated neural activity during the initial presentation in a brain region broadly implicated in top-down control, the dorsolateral prefrontal cortex (dlPFC), could predict subsequent activation in limbic areas relevant to bottom-up affective processing. Using ecological momentary assessment (EMA), we also tested for associations between the aforementioned neuroimaging markers and negative affective states in the two weeks following the experiment. fMRI data revealed that higher initial activation of the dlPFC in AN predicted increased amygdala reactivity during the second fMRI session, which in turn was related to increased self-reported tension during two weeks following the scan. These data suggest that over-control in AN patients may come at a cost including negative affective states on a short (minutes) as well as a longer time scale (days). This mechanism may significantly contribute to the persistence of AN.Entities:
Mesh:
Year: 2021 PMID: 34016948 PMCID: PMC8138008 DOI: 10.1038/s41398-021-01405-8
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 6.222
Basic demographic and clinical variables.
| HC ( | AN ( | |
|---|---|---|
| Age (years) | 16.65 (3.92) | 16.52 (3.88) |
| BMI (kg/m2) | 20.31 (2.28) | 14.42 (1.23)*** |
| BMI-SDS | −0.14 (0.55) | −3.35 (1.08)*** |
| EDI-2 | 141.37 (24.88) | 214.22 (46.21)*** |
| BDI-II | 5.41 (4.25) | 22.25 (10.67)*** |
| STAI-state | 43.46 (5.84) | 56.54 (8.81)*** |
| STAI-trait | 44.29 (6.81) | 55.71 (9.30)*** |
BMI Body-mass-index, BMI-SDS BMI standard deviation score, EDI-2 Eating Disorder Inventory, BDI-II Beck Depression Inventory, STAI State-Trait-Anxiety Inventory. Levels of significance are reported for independent sample t-tests between HC (healthy controls) and AN (Anorexia Nervosa patients); ***significant at p < 0.001.
Results of ROI analyses for phase (2) RX-fMRI data.
| Contrast | ROI | H | XYZ | K | Zmax |
|---|---|---|---|---|---|
| AN > HC | Amygdala | R | 26 −4 −16 | 100 | 5.25 |
| L | −24 −6 −14 | 57 | 3.93 | ||
| HC > AN | – | – | – | – | – |
| Negative > Neutral | Amygdala | R | 24 2 −24 | 9 | 3.54 |
| Insula | L | −36 24 8 | 28 | 4.26 | |
| Neutral > Negative | Insula | R | 8 12 −12 | 72 | 4.87 |
| dlPFC | R | 28 40 42 | 74 | 3.50 | |
H hemisphere, XYZ MNI coordinates, K cluster size (number of voxels), Zmax peak z-value, HC healthy controls, AN Anorexia nervosa patients. All clusters survived whole-brain FWE correction at p < 0.05, with a voxel-wise threshold of p < 0.001 and ROI-specific cluster extent thresholds (see SI 1.4).
Results of regression analyses: Prediction of phase (2) fMRI-RX amygdala activation by phase (1) fMRI-ER dlPFC activation and, as a control analysis, by phase (1) fMRI-ER amygdala activation, moderated by group.
| Phase (2) fMRI-RX: dependent variable | |||||
|---|---|---|---|---|---|
| х̅RXamygdala_L | х̅RXamygdala_R | ||||
| Phase (1) | |||||
| Constant | −0.02 ± 0.26 | 0.93 | −0.14 ± 0.34 | 0.68 | |
| х̅ERdlPFC_Lventral | −0.84 ± 0.53 | 0.12 | −0.49 ± 0.48 | 0.48 | |
| Group | 1.15 ± 0.38 | 1.77 ± 0.50 | |||
| Group*х̅ERdlPFC_Lventral | 1.51 ± 0.75 | 0.30 ± 0.99 | 0.77 | ||
| Constant | −0.07 ± 0.25 | 0.77 | −0.16 ± 0.33 | 0.64 | |
| х̅ERdlPFC_Ldorsal | −1.07 ± 0.49 | −0.92 ± 0.65 | 0.16 | ||
| Group | 1.24 ± 0.36 | 1.65 ± 0.48 | |||
| Group*х̅ERdlPFC_Ldorsal | 1.78 ± 0.71 | 1.51 ± 0.95 | 0.12 | ||
| Constant | −0.06 ± 0.26 | 0.82 | −0.21 ± 0.35 | 0.54 | |
| х̅ERdlPFC_Rdorsal | −0.35 ± 0.38 | 0.37 | −0.14 ± 0.50 | 0.78 | |
| Group | 1.31 ± 0.37 | 1.80 ± 0.49 | |||
| Group *х̅ERdlPFC_Rdorsal | 0.52 ± 0.50 | 0.30 | −0.16 ± 0.65 | 0.80 | |
| Constant | −0.09 ± 0.26 | 0.74 | −0.15 ± 0.34 | 0.65 | |
| х̅ERamygdala_R | −0.49 ± 0.96 | 0.61 | −0.73 ± 1.24 | 0.57 | |
| Group | 1.39 ± 0.37 | 1.72 ± 0.48 | |||
| Group *х̅ERamygdala_R | −0.06 ± 1.20 | 0.96 | 1.09 ± 1.56 | 0.49 | |
Note: All fMRI variables are mean parameter estimates (across conditions). SEM standard error of the mean. *significant at α ≤ 0.05; **significant at α ≤ 0.01, ***significant at α ≤ 0.001.
Fig. 1Prediction of phase (2) fMRI-RX left amygdala activation (х̅RXamygdala_L) by phase (1) fRMI-ER left ventral dlPFC and left dorsal dlPFC activation (х̅ERdlPFC_Lventral and х̅ERdlPFC_Ldorsal), moderated by group.
The linear b coefficients were significantly increased in AN compared to HC (left ventral dlPFC: t(60) = −2.02; p = 0.048; left dorsal dlPFC: t(60) = −2.54, p = 0.014).
Non-standardized β-values of the EMA HLM analyses.
| Predictor (Level C) | Phase (3) EMA outcome variable | |
|---|---|---|
| Tension | Negative Affect | |
| Group | −13.61* | −33.06** |
| Phase (2) fMRI-RX amygdala | −7.67** | −2.71 |
| Phase (2) fMRI-RX amygdala * group | −2.54 | 1.66 |
Notes: Phase (3) tension and negative affect predicted by group, phase (2) fMRI-RX amygdala activation, and their interaction (Level C). Phase (2) fMRI-RX amygdala activation was averaged over the hemispheres. Predictors of Level B (day of study) and Level A (time of day, company, dummy-coded variables for activity) are not displayed; full model can be seen in SI Table 3. Negative affect and tension as measured by EMA questionnaire; lower values indicate more tension and more negative affect. Group was coded −1 = HC (healthy controls), 1 = AN(Anorexia nervosa patients). N = 69. *significant at α ≤ 0.05; **significant at α ≤ 0.01.